Market Overview

Morgan Stanley Sees Sapien Becoming Leading Product Line for Edwards Lifesciences

Share:
Related EW
Lawsuit Against Neovasc Comes Back In Favor Of CardiAQ; Ladenburg Thalmann Downgrades, Removes PT
BTIG Downgrades Johnson & Johnson, Admits Buy Thesis 'Had Some Hits & Misses'
No New Record High For S&P 500, But ETFs Based On It Are Soaring (Investor's Business Daily)

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Edwards Lifesciences (NYSE: EW).

In the report, Morgan Stanley noted, “Sapien should prove to be the leading product line in transcatheter valves into '14 and beyond, supported by clinical data. The TAVR market is likely to continue its expansion, supported by better budgets in Europe, favorable clinical data in lower risk populations, and more deliverable products. A mitral replacement program could drive upside given the larger potential patient pool relative to the aortic space. Higher valve revenue mix supports higher GMs.”

Edwards Lifesciences closed on Thursday at $80.27.

Latest Ratings for EW

DateFirmActionFromTo
Apr 2016CitigroupMaintainsSell
Apr 2016Cowen & CompanyMaintainsOutperform
Apr 2016JP MorganMaintainsOverweight

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (EW)

View Comments and Join the Discussion!